Immunoprecise Historical Balance Sheet

IPA Stock

USD 0.38 0.01 2.56%

Trend analysis of Immunoprecise Antibodies balance sheet accounts such as Total Current Liabilities of 9.8 M or Total Stockholder Equity of 41 M provides information on Immunoprecise Antibodies' total assets, liabilities, and equity, which is the actual value of Immunoprecise Antibodies to its prevalent stockholders. By breaking down trends over time using Immunoprecise Antibodies balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Immunoprecise Antibodies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunoprecise Antibodies is a good buy for the upcoming year.

Immunoprecise Antibodies Inventory

2.58 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

About Immunoprecise Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Immunoprecise Antibodies at a specified time, usually calculated after every quarter, six months, or one year. Immunoprecise Antibodies Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Immunoprecise Antibodies and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Immunoprecise currently owns. An asset can also be divided into two categories, current and non-current.

Immunoprecise Antibodies Balance Sheet Chart

At present, Immunoprecise Antibodies' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 2.3 M, whereas Retained Earnings are projected to grow to (85.7 M).

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net

Add Fundamental

Total Assets

Total assets refers to the total amount of Immunoprecise Antibodies assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunoprecise Antibodies books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Immunoprecise Antibodies balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Immunoprecise Antibodies are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Immunoprecise Antibodies' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.At present, Immunoprecise Antibodies' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 2.3 M, whereas Retained Earnings are projected to grow to (85.7 M).

	2022	2023	2024	2025 (projected)
Other Current Liabilities	2.3M	1.9M	2.2M	2.3M
Total Assets	77.8M	60.0M	69.0M	72.4M

Other Current Liab Total Assets

Immunoprecise Antibodies balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Non Current Liabilities Total	Non Currrent Assets Other	Short Long Term Debt Total	Property Plant And Equipment Gross	Short Term Debt	Inventory	Current Deferred Revenue	Intangible Assets
Total Assets		0.91	0.88	0.97	0.72	-0.3	-0.78	0.87	0.63	0.94	0.62	0.9	0.92	-0.28	0.98	-0.13	0.87	0.79	0.8	-0.3	0.65	0.78	0.59	0.86	0.84	0.89
Other Current Liab	0.91		0.9	0.88	0.58	-0.37	-0.61	0.76	0.68	0.79	0.67	0.9	0.85	-0.32	0.86	-0.29	0.79	0.82	0.68	-0.28	0.55	0.61	0.68	0.83	0.85	0.69
Total Current Liabilities	0.88	0.9		0.79	0.74	-0.07	-0.74	0.91	0.42	0.88	0.41	0.95	0.93	-0.34	0.81	-0.29	0.91	0.6	0.81	-0.28	0.73	0.76	0.82	0.91	0.95	0.78
Total Stockholder Equity	0.97	0.88	0.79		0.56	-0.49	-0.65	0.74	0.76	0.85	0.75	0.81	0.81	-0.24	0.96	-0.12	0.73	0.88	0.65	-0.31	0.48	0.64	0.55	0.76	0.74	0.85
Property Plant And Equipment Net	0.72	0.58	0.74	0.56		0.35	-0.95	0.89	0.05	0.84	0.04	0.82	0.91	-0.18	0.75	0.02	0.93	0.27	0.97	-0.24	0.97	0.99	0.36	0.84	0.79	0.71
Net Debt	-0.3	-0.37	-0.07	-0.49	0.35		-0.25	0.13	-0.91	0.04	-0.92	-0.04	0.05	0.05	-0.3	0.12	0.18	-0.8	0.29	0.11	0.4	0.3	-0.12	0.06	-0.02	-0.05
Retained Earnings	-0.78	-0.61	-0.74	-0.65	-0.95	-0.25		-0.87	-0.14	-0.88	-0.13	-0.8	-0.9	0.27	-0.81	-0.21	-0.91	-0.34	-0.94	0.4	-0.87	-0.97	-0.39	-0.85	-0.75	-0.8
Accounts Payable	0.87	0.76	0.91	0.74	0.89	0.13	-0.87		0.25	0.94	0.24	0.9	0.95	-0.3	0.82	-0.13	0.98	0.46	0.95	-0.19	0.87	0.91	0.59	0.89	0.87	0.84
Cash	0.63	0.68	0.42	0.76	0.05	-0.91	-0.14	0.25		0.32	1.0	0.42	0.34	-0.17	0.63	-0.15	0.22	0.97	0.11	-0.21	-0.01	0.1	0.32	0.31	0.38	0.35
Non Current Assets Total	0.94	0.79	0.88	0.85	0.84	0.04	-0.88	0.94	0.32		0.31	0.9	0.96	-0.27	0.91	-0.08	0.95	0.52	0.93	-0.27	0.78	0.9	0.57	0.91	0.83	0.94
Cash And Short Term Investments	0.62	0.67	0.41	0.75	0.04	-0.92	-0.13	0.24	1.0	0.31		0.41	0.33	-0.12	0.62	-0.15	0.21	0.97	0.1	-0.22	-0.02	0.09	0.31	0.3	0.37	0.34
Net Receivables	0.9	0.9	0.95	0.81	0.82	-0.04	-0.8	0.9	0.42	0.9	0.41		0.97	-0.34	0.88	-0.28	0.94	0.62	0.87	-0.21	0.81	0.83	0.68	0.89	0.97	0.79
Common Stock Shares Outstanding	0.92	0.85	0.93	0.81	0.91	0.05	-0.9	0.95	0.34	0.96	0.33	0.97		-0.32	0.91	-0.17	0.98	0.55	0.95	-0.25	0.88	0.93	0.62	0.95	0.93	0.85
Short Term Investments	-0.28	-0.32	-0.34	-0.24	-0.18	0.05	0.27	-0.3	-0.17	-0.27	-0.12	-0.34	-0.32		-0.27	0.0	-0.29	-0.19	-0.26	-0.1	-0.26	-0.2	-0.3	-0.29	-0.36	-0.27
Other Current Assets	0.98	0.86	0.81	0.96	0.75	-0.3	-0.81	0.82	0.63	0.91	0.62	0.88	0.91	-0.27		-0.05	0.84	0.79	0.8	-0.32	0.66	0.8	0.49	0.83	0.81	0.87
Other Stockholder Equity	-0.13	-0.29	-0.29	-0.12	0.02	0.12	-0.21	-0.13	-0.15	-0.08	-0.15	-0.28	-0.17	0.0	-0.05		-0.13	-0.18	-0.04	-0.65	-0.16	0.05	-0.37	-0.15	-0.33	-0.08
Total Liab	0.87	0.79	0.91	0.73	0.93	0.18	-0.91	0.98	0.22	0.95	0.21	0.94	0.98	-0.29	0.84	-0.13		0.44	0.98	-0.23	0.91	0.95	0.57	0.93	0.9	0.83
Total Current Assets	0.79	0.82	0.6	0.88	0.27	-0.8	-0.34	0.46	0.97	0.52	0.97	0.62	0.55	-0.19	0.79	-0.18	0.44		0.33	-0.26	0.2	0.31	0.44	0.51	0.57	0.53
Non Current Liabilities Total	0.8	0.68	0.81	0.65	0.97	0.29	-0.94	0.95	0.11	0.93	0.1	0.87	0.95	-0.26	0.8	-0.04	0.98	0.33		-0.18	0.94	0.98	0.41	0.88	0.82	0.79
Non Currrent Assets Other	-0.3	-0.28	-0.28	-0.31	-0.24	0.11	0.4	-0.19	-0.21	-0.27	-0.22	-0.21	-0.25	-0.1	-0.32	-0.65	-0.23	-0.26	-0.18		-0.03	-0.26	-0.31	-0.34	-0.21	-0.23
Short Long Term Debt Total	0.65	0.55	0.73	0.48	0.97	0.4	-0.87	0.87	-0.01	0.78	-0.02	0.81	0.88	-0.26	0.66	-0.16	0.91	0.2	0.94	-0.03		0.94	0.38	0.81	0.81	0.65
Property Plant And Equipment Gross	0.78	0.61	0.76	0.64	0.99	0.3	-0.97	0.91	0.1	0.9	0.09	0.83	0.93	-0.2	0.8	0.05	0.95	0.31	0.98	-0.26	0.94		0.38	0.86	0.79	0.79
Short Term Debt	0.59	0.68	0.82	0.55	0.36	-0.12	-0.39	0.59	0.32	0.57	0.31	0.68	0.62	-0.3	0.49	-0.37	0.57	0.44	0.41	-0.31	0.38	0.38		0.7	0.76	0.59
Inventory	0.86	0.83	0.91	0.76	0.84	0.06	-0.85	0.89	0.31	0.91	0.3	0.89	0.95	-0.29	0.83	-0.15	0.93	0.51	0.88	-0.34	0.81	0.86	0.7		0.87	0.81
Current Deferred Revenue	0.84	0.85	0.95	0.74	0.79	-0.02	-0.75	0.87	0.38	0.83	0.37	0.97	0.93	-0.36	0.81	-0.33	0.9	0.57	0.82	-0.21	0.81	0.79	0.76	0.87		0.74
Intangible Assets	0.89	0.69	0.78	0.85	0.71	-0.05	-0.8	0.84	0.35	0.94	0.34	0.79	0.85	-0.27	0.87	-0.08	0.83	0.53	0.79	-0.23	0.65	0.79	0.59	0.81	0.74

Click cells to compare fundamentals

Immunoprecise Antibodies Account Relationship Matchups

Immunoprecise Antibodies balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	67.0M	93.5M	77.8M	60.0M	69.0M	72.4M
Other Current Liab	3.3M	2.6M	2.3M	1.9M	2.2M	2.3M
Total Current Liabilities	6.1M	9.3M	5.9M	8.1M	9.3M	9.8M
Total Stockholder Equity	56.9M	75.3M	57.8M	33.9M	39.0M	41.0M
Property Plant And Equipment Net	4.1M	3.7M	10.7M	16.7M	19.2M	20.2M
Net Debt	(38.3M)	(27.4M)	(1.0M)	10.2M	9.2M	9.7M
Retained Earnings	(29.8M)	(46.5M)	(73.1M)	(100.3M)	(90.2M)	(85.7M)
Accounts Payable	1.3M	3.9M	2.5M	4.1M	4.7M	4.9M
Cash	41.8M	30.0M	8.3M	3.5M	4.0M	4.0M
Non Current Assets Total	18.1M	56.0M	61.0M	48.5M	55.8M	58.6M
Cash And Short Term Investments	41.8M	30.0M	8.3M	3.5M	4.0M	4.1M
Net Receivables	3.6M	3.4M	3.9M	4.1M	4.7M	4.9M
Common Stock Shares Outstanding	16.5M	19.7M	24.9M	25.6M	29.5M	31.0M
Liabilities And Stockholders Equity	67.0M	93.5M	77.8M	60.0M	69.0M	72.4M
Other Current Assets	2.3M	2.5M	2.6M	1.8M	2.1M	2.2M
Other Stockholder Equity	7.2M	9.6M	10.8M	12.4M	11.1M	9.3M
Total Liab	10.0M	18.2M	20.0M	26.1M	30.0M	31.5M
Total Current Assets	48.9M	37.5M	16.8M	11.5M	13.2M	13.9M
Non Current Liabilities Total	4.0M	8.9M	14.1M	17.9M	20.6M	21.7M
Non Currrent Assets Other	79K	82K	86K	561K	504.9K	822.8K
Short Long Term Debt Total	3.5M	2.5M	7.3M	13.7M	15.7M	16.5M
Property Plant And Equipment Gross	4.1M	9.4M	17.1M	21.5M	24.7M	26.0M
Accumulated Other Comprehensive Income	(687K)	(2.5M)	2.6M	2.0M	2.3M	2.4M
Short Term Debt	986K	2.3M	1.1M	1.6M	1.8M	1.1M
Inventory	1.2M	1.6M	2.1M	2.1M	2.5M	2.6M
Current Deferred Revenue	1.1M	1.0M	977K	1.4M	1.6M	1.6M
Intangible Assets	6.1M	32.4M	30.9M	23.6M	27.1M	15.6M
Common Stock	80.1M	114.6M	117.5M	119.8M	137.7M	144.6M
Net Tangible Assets	(1.0M)	43.1M	23.2M	7.7M	8.9M	12.5M
Net Invested Capital	58.5M	76.6M	57.8M	33.9M	39.0M	39.2M
Net Working Capital	42.8M	28.2M	10.9M	3.4M	3.9M	3.7M
Property Plant Equipment	3.1M	4.0M	3.3M	10.4M	12.0M	12.5M
Other Liab	2.6M	1.5M	8.6M	7.9M	9.1M	5.1M
Other Assets	287.6K	163K	476K	437K	393.3K	373.6K
Good Will	7.8M	19.7M	19.2M	7.7M	8.8M	11.8M
Capital Lease Obligations	1.9M	1.2M	7.3M	13.7M	15.7M	16.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
CRM	Salesforce
CRM	Salesforce

When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:

How To Invest In Immunoprecise

Details

Is Immunoprecise Stock a good investment?

Details

What is Immunoprecise Antibodies' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.75)

Revenue Per Share

0.894

Quarterly Revenue Growth

(0)

Return On Assets

(0.14)

Return On Equity

(0.66)

The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunoprecise Historical Balance Sheet

Immunoprecise Antibodies Inventory

2.58 Million

About Immunoprecise Balance Sheet Analysis

Immunoprecise Antibodies Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Immunoprecise Antibodies balance sheet Correlations

Immunoprecise Antibodies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunoprecise Antibodies balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Other Current Assets	+ 0.98	Total Assets
Total Liab	+ 0.98	Accounts Payable
Total Liab	+ 0.98	Common Stock Shares Outstanding
Non Current Liabilities Total	+ 0.98	Total Liab

Property Plant And Equipment Gross	- 0.97	Retained Earnings
Retained Earnings	- 0.95	Property Plant And Equipment Net
Non Current Liabilities Total	- 0.94	Retained Earnings
Cash And Short Term Investments	- 0.92	Net Debt
Total Liab	- 0.91	Retained Earnings
Cash	- 0.91	Net Debt